Mar 19 2012
MabCure Inc., (OTCBB:MBCI) a leading developer of antibody based technology for the diagnosis and treatment of Ovarian, Prostate, Colorectal and other cancers today announced it has entered into an agreement with the City University of New York Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.
These antibodies were developed earlier by MBCI and have shown significant promise in detecting ovarian cancer in blood samples and distinguishing between cancer and benign tumors of the ovaries. The results were presented last year at the annual meeting of the Society of Gynecological Oncologists (SGO) http://www.mabcure.com/MBCI-SGO.pdf
In order to further develop these antibodies as diagnostic reagents, they will be the subject of further evaluation and characterization at CUNY CAT. The work will be carried out in the laboratory of Professor Paul Gottlieb at the City College of New York's Sophie Davis School of Biomedical Education. This contractual agreement will permit the MBCI antibodies to be tested and validated in an independent setting.
Following validation, the Company plans to evaluate the performance of its antibodies in diagnosing ovarian cancer in blood samples obtained from its completed Thai study as well as samples obtained from patients previously admitted to the Department of Gynecologic Oncology, Catholic University Hospital, Leuven, Belgium.
Dr. Amnon Gonenne, CEO, stated, "MabCure looks forward to accomplishing its goals of developing a definitive test for the early detection of ovarian cancer, validating and expanding its earlier results. The interaction with CUNY CAT organization gives us the advantage not only of access to their scientific expertise, but also to participate in the larger mission of the CAT as it seeks to support early stage biotechnology initiatives in the area".
Advanced imaging technology detects undiagnosed metastases in high-risk prostate cancer